Trials / Completed
CompletedNCT03533751
Efficacy, Safety, and Pharmacokinetic Profile of Etokimab (ANB020) in Adult Participants With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, and Pharmacokinetic Profile of ANB020 Administered to Adult Subjects With Moderate-to-Severe Atopic Dermatitis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 302 (actual)
- Sponsor
- AnaptysBio, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed to evaluate the efficacy, safety, and pharmacokinetic (PK) profiles of multiple doses of etokimab in adult participants with atopic dermatitis (AD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Etokimab | Humanized monoclonal antibody, administered by subcutaneous injection |
| DRUG | Placebo | Administered by subcutaneous injection |
Timeline
- Start date
- 2018-06-19
- Primary completion
- 2019-12-03
- Completion
- 2019-12-03
- First posted
- 2018-05-23
- Last updated
- 2023-05-24
- Results posted
- 2023-05-24
Locations
81 sites across 6 countries: United States, Canada, Czechia, Germany, Poland, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03533751. Inclusion in this directory is not an endorsement.